Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Cash & Current Investments for 10 consecutive years, with $525.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 24.18% year-over-year to $525.9 million; the trailing twelve-month figure through Jun 2026 stood at $525.9 million (up 24.18% YoY), and the FY2025 full-year result was $414.1 million, up 69.96% from the prior year.
• Cash & Current Investments grew to $525.9 million in Q2 2026 per KNSA's latest filing, from $468.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $529.3 million in Q3 2025 and bottomed at $138.2 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $309.4 million across 5 years, with a median of $285.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments sank 64.34% in 2022, then surged 86.25% in 2023.
• Over 5 years, Cash & Current Investments stood at $190.6 million in 2022, then gained by 8.27% to $206.4 million in 2023, then gained by 18.05% to $243.6 million in 2024, then jumped by 69.96% to $414.1 million in 2025, then rose by 27.01% to $525.9 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $525.9 million, $468.1 million, and $414.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.